44 Wealth Management LLC Has $3.22 Million Holdings in Sanofi (NASDAQ:SNY)

44 Wealth Management LLC lessened its stake in Sanofi (NASDAQ:SNY - Free Report) by 7.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 66,830 shares of the company's stock after selling 5,031 shares during the quarter. Sanofi comprises 1.2% of 44 Wealth Management LLC's investment portfolio, making the stock its 10th biggest position. 44 Wealth Management LLC's holdings in Sanofi were worth $3,223,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Franklin Resources Inc. boosted its holdings in shares of Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock valued at $208,106,000 after purchasing an additional 395,744 shares in the last quarter. Natixis Advisors LLC lifted its position in shares of Sanofi by 4.1% during the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company's stock worth $165,640,000 after buying an additional 114,133 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock valued at $133,172,000 after buying an additional 399,301 shares in the last quarter. DAVENPORT & Co LLC grew its position in Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock valued at $110,715,000 after acquiring an additional 664,455 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in Sanofi by 938.0% during the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock worth $109,753,000 after acquiring an additional 1,720,972 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Finally, StockNews.com cut shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Sanofi currently has an average rating of "Buy" and an average target price of $60.00.

Sanofi Trading Up 0.1 %

Shares of SNY stock traded up $0.06 during mid-day trading on Wednesday, reaching $54.95. 1,823,142 shares of the stock traded hands, compared to its average volume of 2,414,638. The company has a market cap of $139.45 billion, a price-to-earnings ratio of 22.07, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock's fifty day simple moving average is $51.22 and its two-hundred day simple moving average is $52.56. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.